Related Experiment Videos
Low dose lisuride in advanced Parkinson disease
F Degl'Innocenti1, A Ginanneschi, S Magnolfi
1Clinica Neurologica I, Università di Firenze.
Italian Journal of Neurological Sciences
|August 1, 1987
Summary
Lisuride offers significant therapeutic benefits for advanced Parkinson disease patients unresponsive to L-Dopa. This study shows improved motor function and reduced disability with few side effects.
Area of Science:
- Neurology
- Pharmacology
Background:
- Advanced Parkinson disease presents challenges in managing motor fluctuations.
- Levodopa (L-Dopa) therapy efficacy diminishes in later stages, necessitating alternative treatments.
Purpose of the Study:
- To evaluate the therapeutic efficacy of Lisuride in patients with advanced Parkinson disease.
- To assess Lisuride's impact on motor function and
Main Methods:
- A cohort of 19 patients with advanced Parkinson disease received oral Lisuride (0.6-2.5 mg/day) in combination with L-Dopa.
- Patients were monitored for at least 6 months.
Main Results:
- Significant improvements were observed on the Webster Rating Scale at 1, 3, and 6 months.
- Reductions in patient disability and "on-off" phenomena were noted.
- Lisuride treatment was associated with a low incidence of side effects.
Conclusions:
- Lisuride demonstrates significant therapeutic value as an adjunct therapy for advanced Parkinson disease.
- It effectively improves motor symptoms and reduces disability in patients with suboptimal L-Dopa response.